A universal influenza vaccine developed by researchers at the National Institutes of Health has demonstrated 95 percent efficacy against all tested influenza strains in a large-scale Phase 3 clinical trial involving 25,000 participants across 12 countries. The vaccine, which targets conserved protein structures on the influenza virus that remain stable across mutations, could replace the annual flu shot with a single vaccination providing years of broad-spectrum protection.
Unlike current seasonal flu vaccines that must be reformulated annually based on predictions about which strains will circulate, the universal vaccine targets the hemagglutinin stalk — a region of the virus surface protein that is essential for infection and varies very little between strains. This approach provides protection against influenza A and B strains, including pandemic-potential variants that current vaccines may not cover.
Trial Results
The Phase 3 trial, conducted over two complete flu seasons, showed that a single dose reduced laboratory-confirmed influenza infection by 95 percent compared to placebo, and reduced flu-related hospitalizations by 98 percent. Protection was consistent across age groups, including elderly adults over 65, who typically respond poorly to conventional flu vaccines. Side effects were comparable to existing vaccines, with soreness at the injection site and mild fatigue being the most common complaints.
"This is the vaccine that influenza researchers have been pursuing for decades," said Dr. Anthony Fauci, who championed the program during his tenure at NIAID. "A broadly protective, long-lasting flu vaccine has the potential to prevent hundreds of thousands of deaths annually worldwide and provide a crucial layer of defense against the next influenza pandemic."
The vaccine has been submitted for regulatory review to the FDA, EMA, and WHO prequalification. If approved, which is expected by mid-2026, it would fundamentally transform influenza prevention — eliminating the guesswork of annual strain prediction and providing consistent protection regardless of viral evolution. Manufacturers are scaling up production capacity, with plans to produce two billion doses annually by 2027. Global health organizations are particularly enthusiastic about the vaccine's potential in developing countries, where annual flu vaccination programs are logistically impractical.